You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Guard Therapeutics presents top-line results of Phase 2 (AKITA) study, 2023
By Inderes
Speaker: Tobias Agervald, CEO and Michael Reusch, CMO
Sector: Health care - Pharmaceuticals & Biotechnology
Activity: Audiocast with teleconference
Language: English